FULGENT GENETICS, INC. Foreign Currency Transaction Gain (Loss), before Tax
FULGENT GENETICS, INC. (FLGT) reported Foreign Currency Transaction Gain (Loss), before Tax of $0 for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-07.
Discontinued › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2021-05-07
- FULGENT GENETICS, INC. foreign currency transaction gain (loss), before tax for the quarter ending 2021-03-31 was $0.00, a 100.00% decline year-over-year.
- FULGENT GENETICS, INC. foreign currency transaction gain (loss), before tax for the quarter ending 2020-09-30 was -$3.00K.
- FULGENT GENETICS, INC. foreign currency transaction gain (loss), before tax for the quarter ending 2020-06-30 was $26.00K.
- FULGENT GENETICS, INC. foreign currency transaction gain (loss), before tax for the quarter ending 2020-03-31 was $85.00K.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 3 month | Foreign Currency Transaction Gain (Loss), before Tax 6 month | Foreign Currency Transaction Gain (Loss), before Tax 9 month |
|---|---|---|---|
| 2021-03-31 | $0.00 10-Q · filed 2021-05-07 | ||
| 2020-09-30 | -$3.00K 10-Q · filed 2020-11-09 | $23.00K derived: sum of 2 quarters · filed 2020-11-09 | -$62.00K 10-Q · filed 2020-11-09 |
| 2020-06-30 | $26.00K 10-Q · filed 2020-08-05 | -$59.00K 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $85.00K 10-Q · filed 2021-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |